Press Release
Candel Therapeutics (NASDAQ: CADL) Lead Candidate CAN-2409 Combats Lung, Pancreatic And Prostate Cancers With Fast Track Designation For Three Cancers
–News Direct–
By Jeremy Golden, Benzinga
Immunotherapy has transformed the way cancer is treated, but just 20% to 40% of patients typically respond to FDA-approved immune checkpoint inhibitor (ICI) treatments.
Poor ICI treatment response has been linked to the tumors ability to disguise antigen presentation and generate an immunosuppressive microenvironment. In addition, most conventional immunotherapies are not designed to educate the patients immune system on how to recognize a variety of tumor antigens and neoantigens.
Amid this landscape, a clinical-stage biopharmaceutical company has developed a new multimodal biological approach that leverages the ability of viral gene constructs to activate cancer-killing mechanisms, exposing multiple tumor antigens to the immune system, resulting in vaccination against the tumor while inhibiting the immunosuppressive tumor microenvironment.
Candel Therapeutics, Inc. (NASDAQ: CADL) is developing a product candidate that is being studied in lung, pancreatic and prostate cancers. Candels most advanced viral immunotherapy candidate, CAN-2409, is an investigational off-the-shelf replication-defective adenovirus designed to induce an individualized, systemic immune response against the patients own tumor.
Part of the companys adenovirus platform, CAN-2409 is injected directly into the tumor or target tissue using a localized injection, akin to the standard approach for vaccination.
CAN-2409's adenoviral construct serves as a vector to transport the HSV-thymidine kinase gene into tumor cells at the site of injection. These tumor cells can then express HSV-thymidine kinase, which converts generic, FDA-approved anti-herpes drugs such as ganciclovir, acyclovir and valacyclovir into a toxic nucleotide analog that blocks DNA synthesis in dividing cells.
Cancer cells exposed to the toxic nucleotide analog in the tumor microenvironment have been observed to undergo immunogenic cell death. Simultaneously, the adenoviral serotype 5 capsid protein elicits a strong pro-inflammatory signal in the tumor microenvironment, creating the optimal conditions to induce a specific CD8+ T cell-mediated response against the injected tumor and uninjected distant metastases for broad and systemic anti-tumor activity.
CAN-2409 is currently being studied in an open-label, phase 2 clinical trial in non-small cell lung cancer (NSCLC) and in randomized, controlled, blinded phase 2b and phase 3 clinical trials in prostate cancer. The company has recently released very encouraging data for CAN-2409s ability to improve overall survival in non-metastatic pancreatic cancer, with topline overall survival data in non-small cell lung cancer planned for this quarter (Q2 2024) and results from the prostate clinical trials later this year (Q4 2024).
When it comes to NSCLC, the company previously presented data from the phase 2 clinical trial in which patients received two administrations of CAN-2409 plus prodrug. Those patients demonstrated the following:
1) Increased infiltration of CD8+ cytotoxic T cells in the tumor microenvironment, systemic expansion of effector T cells and increased soluble granzyme B levels in peripheral blood;
2) Favorable changes in the trajectory of tumor progression;
3) Decreased tumor size of target lesions in most patients; and
4) Reduced size of uninjected tumor lesions.
The CAN-2409 immunotherapy antitumor strategy aims to increase the number of long survivors beyond 10 to 13 months.
As previous work has shown that progressive disease could be converted into stable disease in most patients with non-small cell lung cancer after CAN-2409 treatment, the hypothesis is that this will translate into improved survival.
When it comes to pancreatic cancer, the company reported notable improvements in patients with borderline resectable pancreatic ductal adenocarcinoma (PDAC) after experimental treatment with CAN-2409. The estimated overall survival rate was 71.4% at 24 months in CAN-2409-treated patients versus only 16.7% in the control arm after chemoradiation.
In 2023, CAN-2409 received Fast Track Designation for both non-small cell lung cancer and pancreatic cancer, a validation from the FDA on its potential. CAN-2409 plus valacyclovir in combination with continued PD-1/PD-L1 agents is being evaluated in an ongoing, open-label phase 2 clinical trial in patients with late-stage NSCLC and an inadequate response to anti-PD(L)-1 therapy. In 2024, CAN-2409 also received Orphan Drug Designation from the FDA for CAN-2409 in borderline resectable pancreatic cancer.
In the upcoming year, Candel plans to announce data readouts for the following:
1) Phase 2 topline overall survival (OS) data for CAN-2409 in NSCLC, expected in Q2 2024;
2) Phase 2 topline data for CAN-2409 in low-to-intermediate-risk, localized, non-metastatic prostate cancer, expected in Q4 2024;
3) Phase 3 topline data for CAN-2409 in localized intermediate/high-risk prostate cancer, expected in Q4 2024.
Featured photo by National Cancer Institute on Unsplash.
Candel is a clinical stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is currently in ongoing clinical trials in non-small cell lung cancer (NSCLC) (phase 2), borderline resectable pancreatic cancer (phase 2), and localized, non-metastatic prostate cancer (phase 2 and phase 3). CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing investigator-sponsored phase 1 clinical trial in recurrent high-grade glioma (HGG). Finally, Candels enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.
This article includes certain disclosures that contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of development programs, including the timing and availability of additional data, key data readout milestones, including CAN-3110 in HGG; expectations regarding the potential benefits conferred by Fast Track Designation; expectations regarding the therapeutic benefit of its programs, including the potential for its programs to extend patient survival; and expectations regarding cash runway and expenditures. The words may, will, could, would, should, expect, plan, anticipate, intend, believe, estimate, predict, project, potential, continue, target and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on managements current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Companys programs; that final data from our pre-clinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Companys ability to efficiently discover and develop product candidates; the Companys ability to obtain and maintain regulatory approval of product candidates; the Companys ability to maintain its intellectual property; the implementation of the Companys business model, and strategic plans for the Companys business and product candidates, and other risks identified in the Companys SEC filings, including the Companys most recent Quarterly Report on Form 10-Q filed with the SEC, and subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Companys views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.
This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.
Contact Details
Aljanae Reynolds
+1 617-916-5445
Company Website
View source version on newsdirect.com: https://newsdirect.com/news/candel-therapeutics-nasdaq-cadl-lead-candidate-can-2409-combats-lung-pancreatic-and-prostate-cancers-with-fast-track-designation-for-three-cancers-458506267
Candel Therapeutics
COMTEX_453480918/2655/2024-06-07T08:28:02
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
The Mining Future Introduces the Bitmain Antminer KS5 20Th—Efficiency and Profits in Crypto Mining
The Mining Future, one of the leading provider of cryptocurrency mining solutions in Middle East and Latin Amercia, is excited to announce the arrival of the Bitmain Antminer KS5 20Th, a new mining rig designed to help cryptocurrency miners boost their efficiency and profits. With a focus on delivering top performance, the KS5 20Th is here to meet the growing demands of today’s mining world.
The Bitmain Antminer KS5 20Th offers an impressive 20 terahashes per second (TH/s), making it perfect for miners looking to stay ahead in the competitive crypto space of Kaspa mining. Whether it is about mining on small scale or as part of a larger operation, this rig can provide the power any Kaspa miner needs to succeed.
Lower Energy Use, Bigger Profits
One of the biggest challenges for miners is the cost of electricity. The Bitmain Antminer KS5 20Th helps tackle this issue thanks to its high efficiency rates, thus using less energy without sacrificing performance. That means lower electricity bills and a quicker return on investment, allowing it to run a more profitable operation.
Built to Last and Ready for the Future
Not only is the Antminer KS5 20Th powerful, but it is also built to last even in the most tough environments. With a durable design and advanced cooling system, it can handle long hours of continuous operation without impacting its uptime. And with its high performance it can stay ahead of the curve despite the increasing network difficulty and the demands of more power, providing a competitive advantage for its owners.
Simple and Easy to Use for Everyone
The Antminer KS5 20Th has been designed to make it easy to set up and use. Its straightforward controls make it accessible to all types of miners, and with Bitmain’s customer support, you can be sure your mining operation is running smoothly without any hassle.
Hosting Services Now Available
For an even simpler mining experience, the miners can delegate its operations to professional crypto mining hosting service facilities. The Mining Future is now expanded its offering of hosting services for the Bitmain Antminer KS5 20Th. Its hosting solutions provide reliable infrastructure at a very affordable rates, so any miner can focus on just enjoying the profits while leaving all technicalities to the technical experts.
A Smart Investment in the Future of Mining
As cryptocurrency mining continues to grow, having powerful and efficient hardware is more important than ever. The Bitmain Antminer KS5 20Th gives miners the edge they need to stay profitable and competitive in this rapidly changing industry.
For more information or to set up a free consultation, please visit www.theminingfuture.com or contact their team at contact@theminingfuture.com.
About The Mining Future
The Mining Future provides top-notch crypto mining hardware and services, offering the latest technology to obtain maximum efficiency and profitability. Offering reliable equipment and cutting-edge hosting infrastructure, the company enables miners minimize downtime, extend equipment lifespan, and maximize profits.
Contact Details:
Contact Person: Gilbert Corbella
Phone No: 48 535 235 364
Address: Dubai Silicon Oasis, Dubai Digital Park, Building A2, Premises 10800-001, Dubai, United Arab Emirates.
Website URL: https://www.theminingfuture.com/
Email Address: contact@theminingfuture.com
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
The Mining Future, one of the leading provider of cryptocurrency mining solutions in Middle East and Latin Amercia, is pleased to announce an exciting expansion to include the latest Antminer Hosting services. With a focus to staying ahead of the curve, The Mining Future now offers specialized hosting solutions for the latest Antminer models, including the S21 200T, S21 Pro 234T, S21 Hydro 335T, S21 XP Hydro 473T, and KS5 Pro 21T.
This service update addresses the latest releases from Bitmain’s top performing models, as well as accommodating the growing demand for more efficient, high-performing hosting solutions that support the newest technological advancements in crypto mining. By offering cutting-edge hosting solutions for these powerful devices, The Mining Future continues its commitment to enabling miners optimize their mining operations while increasing their profitability.
What’s New?
With the S21 series known for its impressive hashing power and energy efficiency, The Mining Future’s hosting services are designed to ensure maximum uptime and minimal operational costs. Here’s what miners can expect:
- Antminer S21 200T Hosting – Take advantage of the S21 200T’s capabilities with optimized energy consumption and enhanced operational efficiency.
- Antminer S21 Pro 234T Hosting – Experience industry-leading performance with infrastructure designed to support the S21 Pro’s superior hashing power.
- Antminer S21 Hydro 335T and S21 XP Hydro 473T Hosting – Benefit from advanced cooling systems tailored for the S21 Hydro, maximizing productivity without increasing energy costs.
- Antminer KS5 Pro 21T Hosting – Secure a hosting environment that ensures stability and peak performance for the top Kaspa miner model KS5 Pro, guaranteeing continuous operation and zero downtime.
Why Choose The Mining Future for Antminer Hosting?
The Mining Future can provide cutting edge cooling technology, reliable power management, and 24/7 monitoring. Its advanced Antminer Hosting services deliver the highest levels of efficiency and performance for the newest miners in the industry. Their secure, scalable facilities are built to handle the increasing power needs of these cutting-edge machines, giving miners a competitive advantage in today’s fast-paced cryptocurrency market.
For more information or to set up a free consultation, please visit www.theminingfuture.com or contact their team at contact@theminingfuture.com.
About The Mining Future
The Mining Future provides top-notch crypto mining hardware and services, offering the latest technology to obtain maximum efficiency and profitability. Offering reliable equipment and cutting-edge hosting infrastructure, the company enables miners minimize downtime, extend equipment lifespan, and maximize profits.
Contact Details:
Contact Person: Gilbert Corbella
Phone No: 48 535 235 364
Address: Dubai Silicon Oasis, Dubai Digital Park, Building A2, Premises 10800-001, Dubai, United Arab Emirates.
Website URL: https://www.theminingfuture.com/
Email Address: contact@theminingfuture.com
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Australia, 22nd Oct 2024, – Treendale Pet Medical, a leading veterinary hospital in Australind, has expanded its services to pet owners near Dalyellup. The clinic provides a full range of routine and advanced veterinary care, ensuring that pets in the region have access to high-quality medical support.
Offering both routine and specialised treatments, Treendale Pet Medical addresses a variety of pet health needs. Services include general health check-ups, dentistry, senior health screenings, and advanced diagnostics. The hospital also provides specialised care, with expert teams dedicated to areas such as oncology, orthopaedic surgery, and neurology.
Dr. Rob Hill, Director of Treendale Pet Medical, shared the clinic’s commitment to extending services to Dalyellup, “The expansion of services near Dalyellup reflects a continued dedication to providing quality veterinary care in the South West. Pet owners in the area now have convenient access to comprehensive veterinary services, delivered with the same level of care that defines the hospital in Australind.”
Treendale Pet Medical offers a broad spectrum of veterinary services, ranging from preventive care to complex medical treatments. The clinic’s routine services include dental care, imaging, and telemedicine consultations, all aimed at supporting long-term pet health. Preventive measures, such as health screenings and regular check-ups, are essential to maintaining the well-being of pets and identifying potential health issues early.
For pets with more advanced medical needs, Treendale Pet Medical offers specialised services such as cancer treatment, pain management, and orthopaedic surgery. The clinic is equipped with state-of-the-art facilities to handle complex cases, providing solutions for conditions that require expert intervention.
Emergency services are also available at the clinic, ensuring immediate care for pets facing urgent health crises. With a team trained to manage emergencies, Treendale Pet Medical provides critical care when it is most needed.
Dr. Hill also highlighted the clinic’s forward-looking approach to veterinary care, “As advancements in veterinary medicine continue, there is an ongoing commitment to expanding services and introducing new technologies. The goal is to ensure that pets in Dalyellup and surrounding areas benefit from the latest treatments available, regardless of the complexity of their condition.”
Treendale Pet Medical’s comprehensive services include advanced imaging, reproductive services for breeders, and specialist care in dermatology, orthopaedics, and ophthalmology. The hospital’s wide range of offerings is designed to meet the varied health needs of pets, from preventive health management to complex medical procedures.
With the clinic’s location in Australind, pet owners near Dalyellup now have access to expert veterinary care close to home. This expansion ensures that pet health remains a priority in the region, offering families the convenience of comprehensive medical services for their pets without the need for long-distance travel.
For more information about the vet near Dalyellup, Treendale Pet Medical can be contacted at +61 8 9796 1388 or via email at reception@treendalevet.com.au. The clinic is located at 109 The Blvd, Australind WA 6233.
Media Contact
Organization: Treendale Pet Medical
Contact
Person: Dr Rob Hill
Email:
reception@treendalevet.com.au
Contact Number: 61897961388
Address:109 The Blvd
Address 2: Australind WA 6233
Country:Australia
The post Treendale Pet Medical Offers Trusted Vet Services Near Dalyellup appeared first on
Brand News 24.
It is provided by a third-party content
provider. Brand News 24 makes no
warranties or representations in connection with it.
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
The Mining Future Introduces the Bitmain Antminer KS5 20Th—Efficiency and Profits in Crypto Mining
The Mining Future Expands Antminer Hosting Services for S21 Series
Treendale Pet Medical Offers Trusted Vet Services Near Dalyellup
Fragasso Financial Advisors Publishes New Blog Post with Evergreen Tax Planning Tips
Absolutely Princess: A New Children’s Classic by Mayra L Santana Warms Hearts Post Launch
Unusual Machines CEO Discusses Growth and Strategic Plans Post-IPO
-
Press Release1 week ago
Indie Fest Carolina to Feature Dancehall/Reggae Sensation Remedy Live in Charlotte
-
Press Release1 week ago
How DLDCUSDT propels the EV industry forward
-
Press Release1 week ago
Growork: The groundbreaking SaaS platform set to revolutionise business connections in the UAE
-
Press Release1 week ago
SafetyXpress Launches Innovative U-Shaped Bollards for Maximum Protection in Commercial and Industrial Spaces
-
Press Release5 days ago
ZainTECH and Urbi Forge Strategic Partnership to Drive Geospatial Innovation across the MENA Region
-
Press Release6 days ago
PetsMega.com Launches Online Store to Offer Pet Owners a New, Fun, and Affordable Way to Care for Their Pets
-
Press Release1 week ago
The Sad Hamster meme coin HAMMY is Gaining Attention as a Potential Community-driven Success Story
-
Press Release5 days ago
Yijin Hardware Delivers High-Quality Sheet Metal Fabrication Services Worldwide